{"id":30893,"date":"2019-05-15T12:00:00","date_gmt":"2019-05-15T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/"},"modified":"2019-05-15T12:00:00","modified_gmt":"2019-05-15T12:00:00","slug":"euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/nl\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/","title":{"rendered":"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma"},"content":{"rendered":"
\n
\n
\n

Biologicals voor CRSwNP met of zonder astma<\/h2>\n

Nieuwe therapie\u00ebn, zoals biologicals die zich richten op type 2-ontsteking, zijn opkomende behandelingsopties voor pati\u00ebnten met chronische inflammatoire luchtwegaandoeningen, waarmee wordt voldaan aan de behoeften van pati\u00ebnten bij wie de ziekte ernstig ongecontroleerd is. De meerderheid van de pati\u00ebnten met chronische rhinosinusitis met neuspoliepen (CRSwNP) en meer dan de helft van de pati\u00ebnten met astma vertonen een type 2-ontstekingsteken in het neusslijmvlies en\/of de longen. <\/p>\n

EUFOREA organiseerde een multidisciplinaire bijeenkomst van de Expert Board om de positionering van biologicals in de zorgtrajecten voor CRSwNP-pati\u00ebnten met en zonder comorbide astma te bespreken.<\/p>\n

Download het nu voor meer volledige informatie.<\/p>\n

OPEN ACCESS-ARTIKEL<\/strong><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n


\n
\n<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Biologicals voor CRSwNP met of zonder astma Nieuwe therapie\u00ebn, zoals biologicals die zich richten op type 2-ontsteking, zijn opkomende behandelingsopties voor pati\u00ebnten met chronische inflammatoire luchtwegaandoeningen, waarmee wordt voldaan aan de behoeften van pati\u00ebnten bij wie de ziekte ernstig ongecontroleerd is. De meerderheid van de pati\u00ebnten met chronische rhinosinusitis met neuspoliepen (CRSwNP) en meer dan de helft van de pati\u00ebnten met astma vertonen een type 2-ontstekingsteken in het neusslijmvlies en\/of de longen. EUFOREA organiseerde een multidisciplinaire bijeenkomst van de Expert Board om de positionering van biologicals in de zorgtrajecten voor CRSwNP-pati\u00ebnten met en zonder comorbide astma te bespreken. Download het nu voor meer volledige informatie. OPEN ACCESS-ARTIKEL<\/p>\n","protected":false},"author":1,"featured_media":30913,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[267],"tags":[151,152,154,181,223,275],"class_list":["post-30893","news","type-news","status-publish","has-post-thumbnail","hentry","category-publicaties","tag-chronische-respiratoire-aandoeningen-crd","tag-crswnp","tag-zorgverleners","tag-biologicals","tag-astma","tag-publicaties"],"yoast_head":"\nEUFOREA-consensus over biologicals voor CRSwNP met of zonder astma - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma\" \/>\n<meta property=\"og:description\" content=\"Biologicals voor CRSwNP met of zonder astma Nieuwe therapie\u00ebn, zoals biologicals die zich richten op type 2-ontsteking, zijn opkomende behandelingsopties voor pati\u00ebnten met chronische inflammatoire luchtwegaandoeningen, waarmee wordt voldaan aan de behoeften van pati\u00ebnten bij wie de ziekte ernstig ongecontroleerd is. De meerderheid van de pati\u00ebnten met chronische rhinosinusitis met neuspoliepen (CRSwNP) en meer dan de helft van de pati\u00ebnten met astma vertonen een type 2-ontstekingsteken in het neusslijmvlies en\/of de longen. EUFOREA organiseerde een multidisciplinaire bijeenkomst van de Expert Board om de positionering van biologicals in de zorgtrajecten voor CRSwNP-pati\u00ebnten met en zonder comorbide astma te bespreken. Download het nu voor meer volledige informatie. OPEN ACCESS-ARTIKEL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/\",\"name\":\"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"datePublished\":\"2019-05-15T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"width\":427,\"height\":280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/kies-uw-traject\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/","og_locale":"nl_NL","og_type":"article","og_title":"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma","og_description":"Biologicals voor CRSwNP met of zonder astma Nieuwe therapie\u00ebn, zoals biologicals die zich richten op type 2-ontsteking, zijn opkomende behandelingsopties voor pati\u00ebnten met chronische inflammatoire luchtwegaandoeningen, waarmee wordt voldaan aan de behoeften van pati\u00ebnten bij wie de ziekte ernstig ongecontroleerd is. De meerderheid van de pati\u00ebnten met chronische rhinosinusitis met neuspoliepen (CRSwNP) en meer dan de helft van de pati\u00ebnten met astma vertonen een type 2-ontstekingsteken in het neusslijmvlies en\/of de longen. EUFOREA organiseerde een multidisciplinaire bijeenkomst van de Expert Board om de positionering van biologicals in de zorgtrajecten voor CRSwNP-pati\u00ebnten met en zonder comorbide astma te bespreken. Download het nu voor meer volledige informatie. OPEN ACCESS-ARTIKEL","og_url":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","og_image":[{"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/","url":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/","name":"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","datePublished":"2019-05-15T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","width":427,"height":280},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/euforea-consensus-over-biologicals-voor-crswnp-met-of-zonder-astma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/nl\/kies-uw-traject\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"EUFOREA-consensus over biologicals voor CRSwNP met of zonder astma"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/30893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/comments?post=30893"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/30893\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media\/30913"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media?parent=30893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/categories?post=30893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/tags?post=30893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}